Title: Individualized targeted therapy in oncology is highly needed in modern era of Radiation oncology practices!
Author: Major (Dr) M.Q. Baig
DOI: https://dx.doi.org/10.18535/jmscr/v9i9.03
Abstract
Individualized or Personalized therapy is a way of medicine will evolve through the use of specific treatments best suited to an individual genotype. This focuses on the role of personalized medicines in cancer and explores its use in current clinical practice in oncology and the challenges to be overcome to achieve this goal. Therefore cancer therapy presents a unique example of personalized therapy in which an individual’s genotype not only determines therapeutics and toxic response to a drug, but also the nature of a specific tumor
Keywords: Targeted therapy, personalized therapy.
References
- Papac RJ. Origins of cancer therapy. Yale J Biol Med 74: 391-398, 2001.
- Dunn FB. National Cancer Act: leaders reflect on 30 years of progress. J Natl Cancer Inst 94: 8-9, 2002.
- Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
- Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292-302, 2004.
- Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MR, Royston I. Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50: 1022s-1028s, 1990.
- Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 60: 4251-4255, 2000.
- Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumorpenetration of a single-chain Fv and comparison with other immuno-globulin forms. Cancer Res 52: 3402-3408, 1992.
- Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58: 485-490, 1998.
- Hofmeister V, Vetter C, Schrama D, Brocker EB Becker JC. Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer ImmunolImmunother 55: 481-494, 2006.
- Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 5:436-446, 2005.
- Newman R, Alberts J, Anderson D, Carner K, Heard C, Norton F, Raab R, Reff M, Shuey S, Hanna N. "Primatization" of recombinant antibodies for immunotherapy of human diseases: a ma- caque/human chimeric antibody against human CD4. Biotechnology 10: 1455-1460, 1992.